1. A 76-year-old man with a history of stable angina and a previous myocardial infarction is found to have a TSH of 38 mIU/L and a free T4 of 0.4 ng/dL on routine labs. He is asymptomatic for hypothyroidism but endorses mild exertional chest tightness unchanged from his prior baseline. His cardiologist confirms he is at his cardiovascular baseline. He weighs 74 kg. Which of the following represents the most appropriate levothyroxine initiation strategy?
A) Begin levothyroxine at the full weight-based replacement dose of approximately 1.6 mcg/kg/day (118 mcg, rounded to 125 mcg), as the severity of biochemical hypothyroidism (TSH 38 mIU/L) indicates urgent hormone repletion is required to prevent myxedema coma
B) Defer levothyroxine initiation entirely until coronary revascularization is performed, as thyroid hormone replacement is absolutely contraindicated in patients with active ischemic heart disease and stable angina
C) Begin levothyroxine at a low dose of 25 mcg/day and uptitrate by 12.5–25 mcg every 4–6 weeks with clinical and biochemical monitoring, accepting a slower path to euthyroidism to avoid precipitating increased myocardial oxygen demand, angina, or arrhythmia from abrupt normalization of metabolic rate
D) Begin levothyroxine at 50 mcg/day and uptitrate by 50 mcg every 2 weeks to reach the weight-based target within 6 weeks, as the log-linear TSH-T4 relationship means small early dose increments have minimal cardiovascular impact and rapid normalization is preferred to reduce the cardiac risk of prolonged hypothyroidism
E) Begin levothyroxine at 12.5 mcg/day and plan to maintain this dose indefinitely without uptitration, as the goal in elderly patients with coronary artery disease is TSH stabilization within the upper half of the reference range (3.0–4.0 mIU/L) rather than full normalization
ANSWER: C
Rationale:
This vignette tests the appropriate modification of standard levothyroxine dosing in the setting of ischemic heart disease. While full weight-based replacement (approximately 1.6 mcg/kg/day) is appropriate for otherwise healthy adults with hypothyroidism, elderly patients and those with known coronary artery disease require a cautious, low-dose initiation strategy. The reasoning is mechanistically sound: thyroid hormone, acting primarily through TRalpha1 in the heart, increases heart rate, cardiac output, and myocardial oxygen demand. Rapidly restoring euthyroid thyroid hormone levels in a patient whose cardiovascular system has adapted to years of reduced metabolic demand can precipitate worsening angina, myocardial infarction, or atrial fibrillation as the heart is abruptly called upon to meet a higher workload. Standard practice for cardiac patients is to begin at 12.5–25 mcg/day and increase by 12.5–25 mcg every 4–6 weeks — accepting the slower path to biochemical euthyroidism in exchange for cardiovascular safety. TSH is rechecked at each interval; the target TSH remains 0.5–2.5 mIU/L once tolerated.
Option A: Option A is incorrect because beginning at the full replacement dose in an elderly patient with coronary artery disease and stable angina risks precipitating an acute coronary syndrome or arrhythmia; the severity of biochemical hypothyroidism (TSH 38 mIU/L) does not mandate urgent full-dose repletion in an asymptomatic patient without myxedema coma features.
Option B: Option B is incorrect because levothyroxine replacement is not absolutely contraindicated in stable ischemic heart disease; it is required to treat hypothyroidism but must be initiated cautiously at low doses — deferring treatment entirely would prolong the adverse metabolic and cardiovascular consequences of hypothyroidism.
Option D: Option D is incorrect because 50 mcg increments every 2 weeks is too aggressive for a patient with coronary artery disease; this pace of uptitration risks cardiovascular decompensation and does not reflect standard practice for cardiac patients; the log-linear TSH-T4 argument does not justify rapid dose escalation in a high-risk cardiac patient.
Option E: Option E is incorrect because the goal of levothyroxine therapy is full biochemical euthyroidism (TSH within the reference range), not intentional incomplete replacement at the upper reference limit; while the pace of uptitration must be slow in cardiac patients, the eventual target is normal TSH — indefinite maintenance at 12.5 mcg without uptitration would leave this patient severely hypothyroid.
2. A 44-year-old woman with epilepsy and autoimmune hypothyroidism has been stable on levothyroxine 112 mcg daily for 3 years, with TSH consistently 1.2–1.8 mIU/L. Her neurologist adds phenytoin for seizure control. At her 8-week thyroid follow-up, her TSH has risen to 9.4 mIU/L. She reports taking both medications as prescribed with no change in timing or formulation. Which of the following is the most appropriate next step and correctly identifies the pharmacological mechanism responsible?
A) Discontinue phenytoin and substitute a non-enzyme-inducing antiepileptic drug such as levetiracetam, as levothyroxine and phenytoin cannot be safely co-administered due to an irreversible pharmacodynamic interaction at the TSH receptor
B) Check anti-TPO antibodies to determine whether phenytoin has triggered a new autoimmune flare of her Hashimoto's thyroiditis, causing increased thyroid destruction and reducing endogenous T4 contribution to her total T4 pool
C) Reduce the levothyroxine dose to 88 mcg, as phenytoin competitively inhibits intestinal levothyroxine absorption and the currently elevated dose is producing iatrogenic free T4 excess that is being mistakenly read by the TSH assay as hypothyroidism
D) Add liothyronine 5 mcg twice daily to compensate for phenytoin's inhibition of type 2 deiodinase (D2) in the pituitary, which is preventing T4-to-T3 conversion at the thyrotroph and causing a falsely elevated TSH despite adequate circulating T4
E) Increase the levothyroxine dose, as phenytoin activates the pregnane X receptor (PXR), upregulating hepatic CYP3A4 and conjugating enzymes that accelerate levothyroxine glucuronidation and clearance; the appropriate response to this enzyme-induction interaction is to increase levothyroxine to restore TSH to its target range, with recheck in 6 weeks
ANSWER: E
Rationale:
Phenytoin is a potent activator of the pregnane X receptor (PXR), which in turn upregulates the transcription of multiple hepatic drug-metabolizing enzymes including CYP3A4, CYP2C9, and glucuronosyltransferase (UGT) family members. These enzymes catalyze the glucuronidation and sulfation of T4 and T3, accelerating their hepatic clearance and reducing circulating thyroid hormone levels. In a patient on fixed levothyroxine replacement — who has no functional thyroid gland to compensate — this increased clearance lowers circulating free T4, reducing pituitary T3 feedback and driving TSH elevation. Additionally, phenytoin at high concentrations may displace T4 from thyroxine-binding globulin (TBG) binding sites, transiently elevating free T4 measurement while simultaneously reducing total T4 — a confounding effect that can complicate interpretation if only total T4 is measured. The correct management is to increase the levothyroxine dose — typically by 20–30% above the pre-phenytoin requirement — and recheck TSH in 6 weeks to confirm adequate re-titration. Carbamazepine, phenobarbital, and rifampin operate through the same PXR-induction mechanism and require similar levothyroxine dose increases.
Option A: Option A is incorrect because there is no irreversible pharmacodynamic interaction between levothyroxine and phenytoin at the TSH receptor; the interaction is a pharmacokinetic enzyme-induction effect on levothyroxine clearance, and discontinuing phenytoin when seizure control is adequate is not warranted solely for this manageable interaction.
Option B: Option B is incorrect because phenytoin does not trigger autoimmune flares of Hashimoto's thyroiditis; while autoimmune thyroid disease does fluctuate, a TSH rise occurring precisely after initiating a known enzyme-inducing antiepileptic drug in an otherwise stable patient points strongly to the pharmacokinetic interaction rather than a coincident autoimmune exacerbation.
Option C: Option C is incorrect because phenytoin does not competitively inhibit intestinal levothyroxine absorption; phenytoin's interaction with levothyroxine is entirely post-absorptive (hepatic enzyme induction), not pre-absorptive, and the TSH of 9.4 mIU/L indicates underreplacement — not overreplacement.
Option D: Option D is incorrect because phenytoin does not inhibit type 2 deiodinase (D2) in the pituitary; D2 inhibition is the mechanism of amiodarone and PTU — not of phenytoin — and adding liothyronine would be an inappropriate and unnecessarily complex response to what is a straightforward dose-adjustment problem.
3. A 29-year-old woman with Hashimoto's thyroiditis has been stable on levothyroxine 100 mcg daily with a pre-conception TSH of 1.4 mIU/L. She confirms a positive home pregnancy test at approximately 5 weeks gestation and calls her endocrinologist. The endocrinologist checks a TSH at 8 weeks, which has risen to 4.8 mIU/L. She is otherwise well with no thyroid symptoms. Which of the following is the most appropriate next step?
A) Increase the levothyroxine dose immediately — a common approach is to add two extra doses per week (approximately 29% increase) — and recheck TSH in 4 weeks, targeting a first-trimester TSH below 2.5 mIU/L; early fetal neurodevelopment depends entirely on maternal T4 before the fetal thyroid becomes functional at approximately weeks 10–12, making prompt correction critical
B) Maintain the current levothyroxine dose of 100 mcg and recheck TSH at 16 weeks, as a TSH of 4.8 mIU/L in the first trimester is within the broader gestational reference range and requires no dose adjustment until the second trimester when fetal thyroid demand increases
C) Discontinue levothyroxine temporarily, as rising TSH in early pregnancy reflects physiological hCG-mediated TSH suppression reversal and the elevated TSH will self-correct by week 12 without intervention
D) Switch from levothyroxine to liothyronine during pregnancy, as T3 crosses the placenta more readily than T4 and is therefore more effective at supporting fetal brain development during the critical first trimester window
E) Add iodine supplementation at 500 mcg/day to the current levothyroxine regimen, as the rising TSH reflects iodide depletion from increased renal iodide clearance in pregnancy rather than increased TBG-driven levothyroxine demand
ANSWER: A
Rationale:
This vignette requires integrating the physiology of pregnancy-related TBG expansion, fetal thyroid development timing, and the clinical urgency of first-trimester levothyroxine optimization. Rising estrogen in early pregnancy expands TBG, increasing T4 binding capacity, lowering free T4, and raising TSH — even in a previously well-controlled hypothyroid woman on fixed levothyroxine. The fetal thyroid does not become functional until approximately weeks 10–12 of gestation; before this window, the fetus depends entirely on maternal T4 crossing the placenta via specific transporters to support brain development, particularly neuronal migration, myelination, and synaptic formation in the cerebral cortex. A maternal TSH of 4.8 mIU/L at 8 weeks indicates relative T4 deficiency during this critical developmental window. Current guidelines from the American Thyroid Association (ATA) target a first-trimester TSH below 2.5 mIU/L in women on levothyroxine. The practical approach to an immediate dose increase is to add two extra doses per week (taking the usual daily dose on 9 days instead of 7, adding approximately 29% to the weekly dose) while awaiting a more precise titration based on the next TSH result in 4 weeks. Waiting until 16 weeks to recheck would leave suboptimal maternal T4 in place throughout the critical first-trimester fetal brain development window.
Option B: Option B is incorrect because a TSH of 4.8 mIU/L at 8 weeks gestation is above the first-trimester target of 2.5 mIU/L and requires prompt dose adjustment; delaying reassessment to 16 weeks exposes the developing fetal brain to inadequate maternal T4 supply during its most critical developmental window.
Option C: Option C is incorrect because the rising TSH in this patient is not physiological hCG-mediated TSH suppression reversal; hCG's TSH receptor cross-reactivity actually tends to mildly suppress TSH in early pregnancy, not elevate it; the elevated TSH here reflects TBG-driven levothyroxine inadequacy requiring dose increase, not a self-correcting phenomenon.
Option D: Option D is incorrect because T4 (levothyroxine), not T3 (liothyronine), is the preferred form of thyroid hormone supplementation in pregnancy; T4 is the primary form that crosses the placenta via MCT8 and other transporters and is converted locally to T3 in fetal tissues by D2; liothyronine has a short half-life producing peaks and troughs and is not recommended for routine hypothyroidism management in pregnancy.
Option E: Option E is incorrect because the rising TSH in this case reflects TBG expansion driving increased levothyroxine requirement, not iodide depletion; while iodine supplementation is appropriate in pregnancy (approximately 150–250 mcg/day recommended), 500 mcg/day exceeds recommended amounts and could trigger Wolff-Chaikoff inhibition in the fetal thyroid; the correct intervention is levothyroxine dose increase.
4. A 26-year-old woman with Graves' hyperthyroidism is well-controlled on methimazole 10 mg daily with a TSH of 0.9 mIU/L. She unexpectedly becomes pregnant at 6 weeks gestation. Her obstetrician calls the endocrinologist for guidance on thionamide management. Which of the following correctly describes the recommended thionamide strategy for managing Graves' disease throughout this pregnancy?
A) Continue methimazole throughout pregnancy at the current dose, as the risk of fetal harm from uncontrolled hyperthyroidism substantially outweighs any teratogenic risk from methimazole, and switching antithyroid agents during the first trimester introduces unnecessary risk of thyrotoxic relapse
B) Discontinue all antithyroid therapy immediately, as both methimazole and PTU cross the placenta and suppress fetal thyroid function; the fetal thyroid is sufficiently sensitive to thionamides that any maternal thionamide use during pregnancy inevitably produces neonatal hypothyroidism requiring treatment
C) Switch immediately to radioactive iodine (I-131) ablation, which is the preferred definitive treatment for Graves' disease in pregnancy because it eliminates the need for ongoing antithyroid drug use and the associated fetal risks
D) Switch from methimazole to propylthiouracil (PTU) for the first trimester because methimazole is associated with a specific embryopathy (choanal atresia, esophageal atresia, aplasia cutis, and the methimazole embryopathy syndrome) when used in the first trimester; then transition back to methimazole in the second trimester because PTU carries a risk of severe maternal hepatotoxicity with prolonged use that outweighs its continued benefit once the organogenesis-sensitive window has passed
E) Switch to the lowest possible dose of both methimazole and PTU combined, as combination antithyroid therapy using two agents at sub-therapeutic doses reduces fetal thyroid suppression while maintaining adequate maternal thyroid control
ANSWER: D
Rationale:
The management of Graves' disease in pregnancy requires navigating two distinct teratogenic/toxicologic windows. In the first trimester (weeks 6–10 being the most sensitive period), methimazole is associated with a recognized embryopathy syndrome including choanal atresia (narrowing of the nasal passages), esophageal or tracheoesophageal fistula, aplasia cutis (scalp skin defects), and a broader methimazole embryopathy pattern affecting facial and other structures. This teratogenic risk appears to be specific to the first trimester when organogenesis is occurring; PTU does not carry the same embryopathic risk for these specific malformations. PTU is therefore the preferred thionamide during the first trimester of pregnancy when antithyroid therapy is required. However, PTU carries a significant risk of idiosyncratic severe hepatotoxicity — including fulminant hepatic failure requiring liver transplantation — with prolonged use; this risk is substantially greater than that seen with methimazole. The American Thyroid Association (ATA) and Endocrine Society guidelines therefore recommend transitioning back to methimazole at the start of the second trimester (approximately week 14–16), once the organogenesis window has closed and the hepatotoxicity risk of prolonged PTU exposure outweighs its continued benefit. Both drugs cross the placenta and do suppress fetal thyroid function, which is a manageable concern at the lowest effective doses; the goal is to maintain maternal free T4 in the upper-normal range using the minimum effective antithyroid dose.
Option A: Option A is incorrect because continuing methimazole throughout the first trimester ignores the well-documented methimazole embryopathy risk during organogenesis; the transition to PTU for the first trimester is a specific and guideline-endorsed recommendation, not an unnecessary risk.
Option B: Option B is incorrect because while both thionamides do cross the placenta, their use at the lowest effective dose is considered safe when required; neonatal hypothyroidism from maternal thionamide use is a manageable and reversible complication, not an inevitable outcome requiring therapy discontinuation; untreated hyperthyroidism in pregnancy poses greater risk to mother and fetus than carefully managed thionamide therapy.
Option C: Option C is incorrect because radioactive iodine (I-131) is absolutely contraindicated in pregnancy; I-131 crosses the placenta, is avidly concentrated by the fetal thyroid (which begins expressing NIS at approximately weeks 10–12), and would ablate the fetal thyroid, causing permanent congenital hypothyroidism; RAI must not be used at any stage of pregnancy.
Option E: Option E is incorrect because combination antithyroid therapy using two drugs at sub-therapeutic doses is not a recognized or recommended strategy; using two thionamides simultaneously doubles the fetal placental drug exposure without evidence of superior efficacy or reduced fetal suppression; monotherapy at the minimum effective dose is the correct approach.
5. A 48-year-old woman underwent total thyroidectomy 6 months ago for a 3.2 cm papillary thyroid cancer with 4 positive cervical lymph nodes (ATA high-risk disease). She received postoperative I-131 remnant ablation. She is now on levothyroxine 200 mcg daily with a TSH of 0.04 mIU/L and a free T4 of 2.1 ng/dL. She is asymptomatic from a thyroid standpoint. Her primary care physician, concerned about her suppressed TSH and elevated free T4, proposes reducing the levothyroxine dose to normalize TSH. Which of the following best explains why TSH suppression is intentionally maintained in this patient, and what monitoring is appropriate?
A) TSH suppression is maintained because levothyroxine at supraphysiological doses enhances immune surveillance of residual thyroid cancer cells by activating TRalpha1 in circulating NK cells; TSH normalization would impair this immune-mediated cancer control
B) TSH suppression below 0.1 mIU/L is maintained in high-risk differentiated thyroid cancer because TSH is a trophic hormone that stimulates NIS expression and proliferation in any residual differentiated thyroid cancer cells through the TSH receptor/Gs/cAMP pathway; removing this trophic stimulus reduces the risk of recurrence and progression; the risk of sustained TSH suppression (atrial fibrillation, bone loss) must be balanced against recurrence risk, and monitoring should include bone density assessment and cardiac evaluation
C) TSH suppression is maintained because a suppressed TSH is required to keep serum thyroglobulin (Tg) assays interpretable; TSH normalization would stimulate Tg production from both benign and malignant remnant tissue, making it impossible to distinguish recurrent cancer from benign residual tissue on surveillance Tg measurements
D) TSH suppression is maintained because levothyroxine at these doses directly inhibits the BRAF V600E mutation pathway that drives papillary thyroid cancer proliferation; the high free T4 acts as a competitive inhibitor of MEK kinase activity in thyroid cancer cells
E) TSH suppression is no longer recommended for any stage of differentiated thyroid cancer because the cardiovascular and skeletal risks of chronic TSH suppression have been shown in randomized controlled trials to outweigh any oncological benefit; the primary care physician is correct to propose dose reduction
ANSWER: B
Rationale:
Differentiated thyroid cancers (papillary and follicular) arise from follicular cells and, in most cases, retain TSH receptor expression. TSH — by binding its receptor and activating the Gs/adenylyl cyclase/cAMP pathway in thyroid cells — functions as a trophic (growth-stimulating) hormone that drives not only normal thyroid function but also the proliferation and function of TSH-receptor-expressing cancer cells. Maintaining TSH suppression below 0.1 mIU/L reduces this trophic stimulus on any residual cancer cells, theoretically reducing recurrence risk. The benefit of TSH suppression is greatest in high-risk patients (large tumors, lymph node involvement, distant metastases, aggressive histology) and least in low-risk patients with complete remission. For high-risk patients such as this woman — who had a T3 primary tumor with 4 positive nodes and received RAI ablation — current ATA guidelines recommend maintaining TSH below 0.1 mIU/L for at least the first several years of follow-up. However, TSH suppression at these levels carries real risks: sustained subclinical thyrotoxicosis increases atrial fibrillation risk (mediated by TRalpha1 in the heart) and accelerates bone resorption (mediated by TRalpha1 in bone), particularly in postmenopausal women. The correct approach is not to blindly normalize TSH based on primary care concern, but to continue suppression with appropriate monitoring including bone density (DEXA scan) and cardiac assessment, adjusting the suppression target over time as the recurrence risk decreases.
Option A: Option A is incorrect because TSH suppression is not maintained through NK cell TRalpha1 activation; the rationale is entirely based on removing TSH-driven trophic stimulation of cancer cells through the TSH receptor, not through immune surveillance mechanisms.
Option C: Option C is incorrect because while TSH stimulation is used to enhance Tg assay sensitivity (either through withdrawal or rhTSH stimulation), this is done periodically for surveillance — it is not a reason to maintain continuous TSH suppression; in fact, suppressed TSH makes stimulated Tg testing less sensitive if performed without TSH elevation.
Option D: Option D is incorrect because levothyroxine at supraphysiological doses does not inhibit BRAF V600E or MEK kinase; free T4 is not a kinase inhibitor, and the oncological rationale for TSH suppression is entirely through the TSH-receptor/cAMP trophic pathway, not through direct inhibition of MAPK signaling in cancer cells.
Option E: Option E is incorrect because TSH suppression remains an evidence-supported component of management for high-risk differentiated thyroid cancer in current ATA guidelines; while the risk-benefit assessment does shift toward less aggressive suppression as remission is confirmed (moving from TSH <0.1 to TSH 0.1–0.5 mIU/L), abandoning suppression entirely in a high-risk patient at 6 months post-ablation is not guideline-concordant.
6. A 61-year-old man with metastatic non-small cell lung cancer is receiving pembrolizumab (an anti-PD-1 immune checkpoint inhibitor). At week 8 of therapy, his TSH is 0.08 mIU/L with a free T4 of 2.4 ng/dL. He reports mild palpitations and heat intolerance. By week 16, his TSH has risen to 22 mIU/L with a free T4 of 0.5 ng/dL and he now complains of fatigue and cold intolerance. His oncologist asks whether to start methimazole for the initial thyrotoxic phase and then levothyroxine for the hypothyroid phase. Which of the following best describes the appropriate management of this biphasic thyroid pattern?
A) Start methimazole for the thyrotoxic phase at week 8, as the immune checkpoint inhibitor has generated TSH receptor-stimulating antibodies (TRAb) producing Graves-like hyperthyroidism requiring antithyroid therapy; transition to levothyroxine only after the Graves' disease is confirmed in remission by negative TRAb
B) Stop pembrolizumab immediately at week 8 when thyrotoxicosis is detected, as immune-related thyroid adverse events are a contraindication to continued checkpoint inhibitor therapy; re-initiation of pembrolizumab is not permitted after any grade of thyroid immune-related adverse event
C) Do not start methimazole for the thyrotoxic phase — this is a destructive thyroiditis pattern in which preformed hormone is released from pembrolizumab-damaged follicular cells, not from new synthesis driven by active TPO; methimazole would be ineffective and is not indicated; symptomatic management with beta-blockers is appropriate for the thyrotoxic phase; start levothyroxine for the subsequent hypothyroid phase, which is often permanent
D) Treat both phases with glucocorticoids: high-dose prednisone during the thyrotoxic phase to suppress the inflammatory destruction, then taper; if hypothyroidism develops despite glucocorticoid therapy, this indicates a more severe pembrolizumab toxicity grade requiring permanent pembrolizumab discontinuation
E) The biphasic pattern of transient thyrotoxicosis followed by hypothyroidism indicates the patient has developed de novo autoimmune polyglandular syndrome type 2 from pembrolizumab; endocrinology referral for comprehensive autoimmune panel is required before any thyroid treatment is initiated
ANSWER: C
Rationale:
This vignette illustrates the essential mechanistic distinction that determines appropriate management of ICI-induced thyroid dysfunction. The biphasic pattern — transient thyrotoxicosis (weeks 6–12) followed by hypothyroidism — is the hallmark of immune-related painless thyroiditis, not Graves' disease. Checkpoint inhibitors release autoreactive T cells from PD-1-mediated inhibition, allowing them to infiltrate and destroy thyroid follicular cells. This follicular cell destruction releases preformed stored thyroid hormones from damaged colloid, producing the transient thyrotoxic phase without any increase in new hormone synthesis. Because TPO is not overactive in this process — the thyrotoxicosis is from hormone release, not synthesis — thionamide drugs (methimazole, PTU), which work by blocking TPO-mediated organification, are pharmacologically ineffective and should not be used. Symptomatic management with beta-blockers (propranolol or atenolol) for palpitations and heart rate control is appropriate during the transient thyrotoxic phase. As follicular stores are depleted and ongoing immune destruction continues, the patient transitions into hypothyroidism — typically permanent because the immune process irreversibly damages the follicular cell population. Levothyroxine replacement is then initiated for long-term management. Pembrolizumab should generally be continued unless the thyroid toxicity is severe (grade 3–4); thyroid immune-related adverse events are managed without discontinuing the cancer therapy in most cases.
Option A: Option A is incorrect because ICI thyroiditis is not Graves' disease; the mechanism is destructive thyroiditis (T-cell-mediated follicular cell destruction releasing preformed hormone), not TSH receptor antibody-driven new synthesis; methimazole has no effect on hormone already stored in colloid.
Option B: Option B is incorrect because immune-related thyroid adverse events are generally not a reason to stop checkpoint inhibitor therapy; thyroid dysfunction (grades 1–2) is managed with hormone therapy as needed while continuing the cancer treatment; stopping pembrolizumab would deprive the patient of effective oncological therapy for a manageable endocrine side effect.
Option D: Option D is incorrect because glucocorticoids are not standard management for ICI-induced thyroiditis; high-dose glucocorticoids are reserved for severe immune-related adverse events such as immune-mediated pneumonitis, myocarditis, and colitis — not for routine thyroiditis; the thyrotoxic phase of ICI thyroiditis is generally mild and self-limited, not requiring immunosuppression.
Option E: Option E is incorrect because the biphasic thyroid pattern of ICI thyroiditis is not autoimmune polyglandular syndrome type 2; while ICI therapy can trigger polyglandular endocrinopathy (including adrenal insufficiency), the pattern described here — thyrotoxicosis followed by hypothyroidism — is the classical and common ICI thyroiditis pattern, not a newly developed APS-2, and management should not be deferred for comprehensive autoimmune evaluation before initiating appropriate treatment.
7. A 57-year-old man with a large unresectable hepatocellular carcinoma (HCC) measuring 14 cm develops progressive severe hypothyroidism over 4 months with a TSH of 89 mIU/L and free T4 of 0.2 ng/dL. He has no prior thyroid history, no thyroid antibodies, and normal thyroid ultrasound. Levothyroxine is initiated at 1.6 mcg/kg/day but his TSH remains markedly elevated at 68 mIU/L after 6 weeks of apparent compliance. His oncologist suspects a tumor-related mechanism. Which of the following best explains the pharmacological basis of this patient's unusually high levothyroxine requirement?
A) The large hepatocellular carcinoma has replaced sufficient functioning liver parenchyma to impair hepatic UGT enzyme activity, paradoxically reducing levothyroxine clearance and causing the hormone to accumulate in the portal circulation rather than reaching the systemic thyroid hormone pool detectable by the pituitary
B) Hepatocellular carcinoma cells overexpress thyroxine-binding globulin (TBG) and secrete it into the portal circulation, creating an enormous TBG sink that binds levothyroxine before it can reach peripheral tissues; free T4 is unmeasurably low because virtually all levothyroxine administered is immediately sequestered by tumor-derived TBG
C) Hepatocellular carcinoma impairs intestinal levothyroxine absorption by reducing bile acid secretion, creating a malabsorption syndrome specific to lipophilic hormones; the solution is intravenous rather than oral levothyroxine to bypass the bile acid-dependent absorption step
D) The TSH of 89 mIU/L is caused by the hepatocellular carcinoma secreting a TSH-like glycoprotein that cross-reacts with the standard TSH immunoassay; actual TSH is normal and the patient does not require levothyroxine at all
E) Large hepatocellular carcinomas and other solid tumors can overexpress type 3 deiodinase (D3), creating a massive intra-tumoral sink that continuously inactivates circulating T4 to reverse T3 and T3 to T2; this "consumptive hypothyroidism" can require levothyroxine doses far exceeding standard weight-based calculations — sometimes 3–4 times higher — to maintain adequate circulating thyroid hormone levels
ANSWER: E
Rationale:
This vignette illustrates consumptive hypothyroidism — a rare but important cause of profound, refractory hypothyroidism in patients with large solid tumors. Type 3 deiodinase (D3), which normally inactivates thyroid hormones during fetal development and is re-expressed in peripheral tissues during critical illness, can be massively overexpressed in certain solid tumors — most notably large vascular tumors such as hepatic hemangiomas, hepatocellular carcinomas, gastrointestinal stromal tumors, and large fibromas. When a tumor expressing enormous quantities of D3 is present, the tumor functions as a metabolic sink that continuously converts circulating T4 to inactive reverse T3 and circulating T3 to inactive T2. The rate of T4 inactivation by the tumor can exceed the capacity of even aggressive levothyroxine replacement to restore normal circulating levels — resulting in persistently elevated TSH despite apparently adequate dosing. The key clinical clues are: no prior thyroid history, normal thyroid gland appearance on ultrasound, absent thyroid antibodies, and the temporal association with a large vascular tumor. Management may require levothyroxine doses far above the standard 1.6 mcg/kg/day — sometimes with addition of liothyronine to provide T3 directly — and definitive treatment is tumor reduction or resection when feasible.
Option A: Option A is incorrect because hepatic parenchymal replacement does not reduce levothyroxine clearance in a way that sequesters the hormone in the portal circulation; levothyroxine enters systemic circulation via intestinal absorption, not via hepatic secretion, and even significantly impaired hepatic conjugation does not create a portal sequestration effect.
Option B: Option B is incorrect because hepatocellular carcinoma cells do not secrete TBG into the circulation; TBG is synthesized by normal hepatocytes and its levels fall (not rise) with significant liver disease; a massive TBG secretion mechanism is not a recognized feature of HCC.
Option C: Option C is incorrect because levothyroxine absorption is not bile acid-dependent; it is absorbed by passive diffusion and facilitated transport across the small intestinal epithelium and does not require bile acids for solubilization in the way that fat-soluble vitamins do; IV levothyroxine bypasses absorption but would not address the underlying D3-mediated inactivation.
Option D: Option D is incorrect because hepatocellular carcinoma does not secrete TSH-like glycoproteins causing assay cross-reactivity; the TSH elevation in this patient is real and reflects genuine hypothyroidism from massive T4 inactivation by tumor-expressed D3; ectopic TSH secretion by HCC is not a recognized clinical syndrome.
8. A 63-year-old man with metastatic renal cell carcinoma started sunitinib 3 months ago and is tolerating it well with evidence of partial tumor response. Routine labs show TSH 14.2 mIU/L and free T4 0.6 ng/dL. His pre-treatment TSH was 1.8 mIU/L. He is experiencing fatigue, but his oncologist is unsure whether fatigue is from sunitinib itself or from new hypothyroidism. Which of the following represents the most appropriate management?
A) Start levothyroxine replacement therapy targeting a TSH of 0.5–2.5 mIU/L, continue sunitinib at the current dose, and recheck TSH every 2–3 months; TKI-induced hypothyroidism is an expected and manageable adverse effect that should not prompt sunitinib dose reduction or discontinuation
B) Discontinue sunitinib immediately, as TKI-induced hypothyroidism is a dose-limiting toxicity that mandates permanent drug discontinuation; restart only after TSH normalizes spontaneously, which typically occurs within 6–8 weeks of stopping
C) Begin high-dose levothyroxine at 3.0 mcg/kg/day to aggressively restore euthyroidism rapidly, as prolonged hypothyroidism in patients with active malignancy accelerates tumor progression by reducing immune surveillance
D) Perform radioiodine uptake scan before initiating levothyroxine to determine whether hypothyroidism is from NIS downregulation or from thyroid vasculature damage; only NIS-downregulation hypothyroidism responds to oral levothyroxine
E) Withhold levothyroxine and attribute the TSH elevation to sick euthyroid syndrome from the underlying malignancy; recheck thyroid function only if TSH exceeds 20 mIU/L or the patient develops clinical myxedema features
ANSWER: A
Rationale:
TKI-induced hypothyroidism — including that caused by sunitinib, sorafenib, and lenvatinib — is an expected class effect occurring in approximately 36–71% of patients on long-term sunitinib therapy, making it one of the most common endocrine adverse events in oncology practice. The mechanism involves multiple concurrent pathways: upregulation of type 3 deiodinase (D3) increasing T4 inactivation, reduced NIS expression impairing thyroidal iodide uptake and synthesis, and direct thyroid microvascular damage from VEGFR inhibition. When biochemical hypothyroidism is confirmed (elevated TSH with low-normal or low free T4), levothyroxine replacement is indicated regardless of whether symptoms are clearly attributable to hypothyroidism, because untreated hypothyroidism adds to fatigue, impairs quality of life, and may affect cardiovascular function in patients already stressed by cancer therapy. Critically, TKI-induced hypothyroidism is not a reason to reduce or stop the sunitinib dose — the oncological benefit of continuing effective cancer therapy substantially outweighs the manageable endocrine adverse effect, which is fully correctable with levothyroxine. Monitoring TSH every 2–3 months during sunitinib therapy is standard oncological endocrinology practice.
Option B: Option B is incorrect because TKI-induced hypothyroidism is not a dose-limiting toxicity requiring permanent drug discontinuation; it is a manageable adverse effect treated with levothyroxine while the TKI continues; stopping effective cancer therapy for a correctable endocrine side effect would deprive the patient of a treatment producing partial tumor response.
Option C: Option C is incorrect because 3.0 mcg/kg/day substantially exceeds the standard full replacement dose of 1.6 mcg/kg/day and would likely produce iatrogenic thyrotoxicosis; there is no evidence that aggressive over-replacement improves immune surveillance against cancer, and the proposed mechanism is not supported by evidence.
Option D: Option D is incorrect because radioiodine uptake scanning is not required before starting levothyroxine replacement for TKI-induced hypothyroidism; the mechanism of hypothyroidism in TKI therapy is multi-factorial and well-characterized, and levothyroxine effectively corrects the hormone deficiency regardless of which specific mechanism predominates; RAI scanning would expose the patient to unnecessary radiation and delay needed treatment.
Option E: Option E is incorrect because a TSH of 14.2 mIU/L with a low free T4 in a patient whose pre-treatment TSH was normal is not sick euthyroid syndrome; sick euthyroid syndrome produces a low or low-normal TSH, not a markedly elevated TSH, and withholding levothyroxine until TSH exceeds 20 mIU/L would prolong unnecessary hypothyroidism with attendant symptoms and cardiovascular consequences.
9. A 71-year-old man with persistent atrial fibrillation was started on amiodarone 6 weeks ago after failing other antiarrhythmic agents. Routine thyroid function tests are ordered. Results: TSH 7.2 mIU/L (reference 0.4–4.0), free T4 1.9 ng/dL (reference 0.8–1.8), T3 62 ng/dL (reference 80–200), reverse T3 elevated. He has no symptoms of either hypothyroidism or hyperthyroidism, and his ventricular rate is well-controlled. His cardiologist asks whether to start levothyroxine. Which of the following represents the correct interpretation and management?
A) The elevated TSH confirms amiodarone-induced hypothyroidism from sustained Wolff-Chaikoff inhibition; levothyroxine 50 mcg daily should be started immediately and titrated to TSH normalization over 6 weeks
B) The elevated free T4 with elevated TSH constitutes a biochemically impossible pattern indicating a malfunctioning immunoassay; both TSH and free T4 should be repeated using a different assay platform before any clinical decision is made
C) The pattern indicates amiodarone-induced type 1 thyrotoxicosis driven by iodine excess; thionamides should be started urgently, as the elevated TSH represents a pituitary resistance pattern that is a known complication of iodine-excess thyrotoxicosis
D) This thyroid function pattern — mildly elevated TSH, elevated free T4, reduced T3, elevated rT3 — is the expected pharmacological signature of amiodarone initiation within the first 3 months, reflecting D1 inhibition (reducing T4-to-T3 conversion, raising free T4 and rT3) and reduced T3-mediated pituitary feedback (mildly elevating TSH); no thyroid intervention is required; TSH should be rechecked at 3 months to confirm resolution or detect emerging true thyroid dysfunction
E) The pattern represents early amiodarone-induced type 2 thyrotoxicosis from destructive thyroiditis; prednisone 40 mg daily should be started and amiodarone discontinued after cardiology consultation, as the mildly elevated TSH reflects early pituitary resistance before full TSH suppression develops
ANSWER: D
Rationale:
This vignette requires distinguishing the expected pharmacological effects of early amiodarone therapy from true thyroid disease. Amiodarone contains approximately 37% iodine by weight and exerts multiple effects on thyroid hormone metabolism. Within the first 3 months of therapy, the characteristic biochemical pattern includes: elevated free T4 (from competitive D1 inhibition reducing T4-to-T3 conversion, leaving more T4 in circulation, and from TBG displacement by amiodarone metabolites); reduced T3 (from D1 inhibition reducing peripheral T4-to-T3 conversion); elevated rT3 (from D1 inhibition reducing rT3 clearance and from D3-mediated T4-to-rT3 conversion); and mildly elevated TSH up to 2–3 times the upper reference limit (from reduced T3-mediated pituitary feedback, since T3 is the principal suppressor of TSH). This entire pattern is a pharmacodynamic consequence of D1 inhibition — not thyroid disease — and resolves to a new pharmacological steady state over several months. No thyroid intervention is warranted. The correct action is to recheck TSH at 3 months: if TSH remains elevated or rises further beyond 2–3× the upper reference limit after 3 months, amiodarone-induced hypothyroidism requiring levothyroxine becomes the appropriate diagnosis. A suppressed TSH after 3 months would signal amiodarone-induced thyrotoxicosis requiring differentiation and treatment.
Option A: Option A is incorrect because a TSH of 7.2 mIU/L at 6 weeks of amiodarone therapy, in the context of an elevated free T4 and reduced T3 (the classic early pattern), does not represent established hypothyroidism requiring levothyroxine; initiating levothyroxine at this point would be premature and risks producing iatrogenic thyrotoxicosis once the pharmacological pattern resolves.
Option B: Option B is incorrect because the pattern of mildly elevated TSH with elevated free T4 is not biochemically impossible in the context of amiodarone; it is specifically explained by D1 inhibition simultaneously raising T4 while lowering T3-mediated pituitary feedback, and is well-documented in the pharmacology literature as an expected early amiodarone effect.
Option C: Option C is incorrect because the elevated TSH in this scenario does not indicate thyrotoxicosis; thyrotoxicosis produces a suppressed TSH, not an elevated one; the described pattern (elevated TSH + elevated free T4) is the expected early amiodarone D1-inhibition pattern, not iodine-excess thyrotoxicosis with pituitary resistance.
Option E: Option E is incorrect because type 2 amiodarone thyrotoxicosis produces a suppressed TSH and markedly elevated free T4, not a mildly elevated TSH; pituitary resistance to thyroid hormone is a rare syndrome unrelated to amiodarone, and prednisone is the treatment for established type 2 AIT — not for the expected early biochemical changes of amiodarone initiation.
10. A 34-year-old woman with Hashimoto's thyroiditis and recently diagnosed celiac disease (confirmed on duodenal biopsy) is currently on levothyroxine 200 mcg daily — well above the expected weight-based full replacement dose for her 58 kg frame (expected ~93 mcg/day). Despite this dose, her TSH remains elevated at 11.6 mIU/L. She reports taking levothyroxine 45 minutes before breakfast every morning. She has started a strict gluten-free diet 2 months ago. Which of the following represents the most appropriate next management step?
A) Further increase the levothyroxine tablet dose to 250 mcg daily and recheck TSH in 6 weeks, as the active intestinal inflammation of celiac disease is likely still resolving and the dose will self-adjust downward as mucosal healing progresses
B) Switch to liquid levothyroxine solution or soft gelatin capsule formulation, which does not require tablet dissolution and is significantly less sensitive to the impaired intestinal absorptive surface of celiac disease; concurrently ensure rigorous adherence to gluten-free diet to allow intestinal mucosal healing, which will progressively restore normal levothyroxine absorption over months
C) Add calcium carbonate 500 mg with each levothyroxine dose, as calcium chelation of unabsorbed levothyroxine in the jejunum will paradoxically increase hormone bioavailability in a damaged intestinal epithelium by protecting the hormone from luminal degradation
D) Switch from oral to intramuscular levothyroxine injections, which bypass the gastrointestinal tract entirely; intramuscular levothyroxine is the standard of care for all patients with significant intestinal malabsorption syndromes including celiac disease
E) Perform a small-bowel radionucleotide motility study to determine the rate of levothyroxine transit through the jejunum; if transit time is less than 30 minutes, prescribe an extended-release levothyroxine preparation that delivers hormone over 4–6 hours to allow adequate contact time with absorptive enterocytes
ANSWER: B
Rationale:
This vignette illustrates levothyroxine malabsorption from celiac disease — one of the most important causes of refractorily elevated TSH despite escalating tablet doses. Celiac disease produces villous atrophy and crypt hyperplasia in the proximal small intestine (duodenum and jejunum), precisely the region where levothyroxine is absorbed. The damaged and flattened intestinal epithelium has a markedly reduced absorptive surface area, significantly impairing levothyroxine absorption from standard tablet formulations. Standard tablets require: dissolution in gastric acid; release of levothyroxine into solution; and uptake across intact enterocyte brush border. All three steps are compromised by celiac disease. Liquid levothyroxine solution and soft gelatin capsule formulations bypass the tablet dissolution requirement and deliver levothyroxine in a form that can be absorbed through whatever functional epithelium remains — achieving significantly better bioavailability in malabsorptive states. Several pharmacokinetic studies have demonstrated that celiac patients absorb liquid or soft-gel levothyroxine substantially better than tablets, often allowing dose reduction once the formulation is switched. Simultaneously, rigorous adherence to a gluten-free diet allows intestinal mucosal healing — gradual recovery of villous architecture over months — which progressively restores normal tablet absorption and typically necessitates dose reduction over time. Simply escalating the tablet dose is a temporizing measure that does not address the root formulation-malabsorption problem.
Option A: Option A is incorrect because further escalating the tablet dose to 250 mcg without addressing the formulation mismatch with celiac disease malabsorption continues to use a delivery system that the patient cannot adequately absorb; switching formulation addresses the mechanism, whereas dose escalation does not.
Option C: Option C is incorrect because calcium carbonate reduces levothyroxine absorption by forming insoluble complexes in the gastrointestinal lumen; adding calcium would worsen, not improve, levothyroxine absorption and is the opposite of correct management.
Option D: Option D is incorrect because intramuscular levothyroxine injection is not a standard or approved route of administration for chronic hypothyroidism; levothyroxine is available for intravenous use (for myxedema coma) but not as a routine intramuscular formulation, and IV administration is reserved for acute critical situations, not chronic malabsorption management.
Option E: Option E is incorrect because small-bowel motility studies and extended-release levothyroxine preparations are not established tools in the management of celiac disease-related levothyroxine malabsorption; the evidence-based approach is formulation switching to liquid or soft-gel preparations combined with dietary treatment of the underlying celiac disease.
11. A 72-year-old woman is found incidentally to have a TSH of 6.8 mIU/L on routine labs ordered by her internist. Her free T4 is 0.9 ng/dL (reference 0.8–1.8 ng/dL). She denies fatigue, cold intolerance, constipation, weight gain, or cognitive complaints. Her physical exam is unremarkable; she has no goiter. Anti-TPO antibodies are mildly positive at 82 IU/mL. She asks her physician whether she needs thyroid medication. Which of the following represents the most evidence-aligned management approach?
A) Begin levothyroxine 50 mcg immediately, as mildly positive anti-TPO antibodies confirm autoimmune thyroiditis that will inevitably progress to overt hypothyroidism; early treatment prevents the cardiovascular consequences of prolonged subclinical hypothyroidism in elderly patients
B) Begin levothyroxine at full weight-based replacement dose (1.6 mcg/kg/day), as a TSH of 6.8 mIU/L in a 72-year-old woman represents clinically significant subclinical hypothyroidism with high risk for atrial fibrillation and dementia; aggressive early treatment is required to prevent cognitive decline
C) Refer immediately for thyroid scintigraphy to classify the etiology of subclinical hypothyroidism before any treatment decision; levothyroxine should not be initiated without imaging confirmation of Hashimoto's thyroiditis versus other causes
D) Begin levothyroxine and target a TSH of 0.1–0.5 mIU/L, applying the same TSH suppression target used in thyroid cancer management, as elderly patients have reduced TSH-receptor sensitivity and require lower TSH levels to achieve adequate peripheral T4 delivery to tissues
E) Observe without levothyroxine, recheck TSH and free T4 in 6–12 months, and counsel the patient that current evidence does not support routine levothyroxine treatment for subclinical hypothyroidism with TSH below 10 mIU/L in asymptomatic elderly patients; the TRUST trial found no benefit from levothyroxine in this population, and treatment carries risks of iatrogenic thyrotoxicosis, atrial fibrillation, and bone loss in older patients
ANSWER: E
Rationale:
This vignette tests the appropriate application of evidence-based guidelines for subclinical hypothyroidism — defined as an elevated TSH with a normal free T4. Subclinical hypothyroidism is common in elderly women (prevalence 4–8% over age 65), and the management decision is nuanced. Current ATA guidelines and the evidence base support the following framework: levothyroxine is generally recommended when TSH is above 10 mIU/L regardless of symptoms; when symptoms clearly attributable to hypothyroidism are present at any TSH elevation; or during pregnancy. For asymptomatic patients with TSH between 4 and 10 mIU/L — particularly elderly patients — the evidence for routine levothyroxine therapy is weak and the TRUST trial (Thyroid Hormone Replacement for Untreated Older Adults with Subclinical Hypothyroidism Trial, published 2017) specifically addressed this question in patients over 65 years with a TSH of 4.6–19.9 mIU/L: levothyroxine produced no benefit in hypothyroid symptoms, quality of life, executive function, or hand grip strength compared to placebo over 12 months. This landmark trial provided strong evidence that routine treatment of mild-to-moderate subclinical hypothyroidism in the elderly does not improve outcomes. Additionally, levothyroxine in elderly patients risks iatrogenic subclinical thyrotoxicosis from overtreatment, which itself increases atrial fibrillation risk and accelerates bone loss — adverse effects that outweigh any hypothetical benefit in asymptomatic patients with TSH below 10 mIU/L. The appropriate approach is observation with TSH monitoring at 6–12 months.
Option A: Option A is incorrect because positive anti-TPO antibodies, while predicting a higher rate of TSH progression over time, do not independently justify levothyroxine initiation in an asymptomatic elderly patient with TSH of 6.8 mIU/L; TSH monitoring is appropriate, but automatic treatment for antibody positivity alone is not evidence-based.
Option B: Option B is incorrect because full weight-based replacement dosing is not appropriate for subclinical hypothyroidism, which by definition has a normal free T4; and characterizing a TSH of 6.8 mIU/L as high-risk for atrial fibrillation and dementia significantly overstates the evidence; the TRUST trial showed no meaningful benefit from levothyroxine in this population.
Option C: Option C is incorrect because thyroid scintigraphy is not required before making a management decision about subclinical hypothyroidism in a patient with anti-TPO antibodies; the combination of mildly elevated TSH, normal free T4, and positive anti-TPO antibodies is consistent with Hashimoto's thyroiditis, and imaging does not change the clinical approach.
Option D: Option D is incorrect because TSH suppression targeting (0.1–0.5 mIU/L) is reserved for post-thyroidectomy thyroid cancer management, not for subclinical hypothyroidism; applying cancer suppression targets to an elderly patient with mild subclinical hypothyroidism would cause iatrogenic thyrotoxicosis.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.